Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q3 FY26 results · Oct–Dec 2025
Dr. Lal Path Labs reported revenue from operations of ₹659.80 crore (up 10.6% from Q3 FY25) and net profit of ₹91.40 crore (down 6.8% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 659.80 | 596.70 | +10.6% | 730.60 | −9.7% |
| Other income | 24.40 | 25.10 | −2.8% | 24.80 | −1.6% |
| Total income | 684.20 | 621.80 | +10.0% | 755.40 | −9.4% |
| Profit before tax | 124.30 | 138.30 | −10.1% | 203.60 | −38.9% |
| Net profit for the period | 91.40 | 98.10 | −6.8% | 152.20 | −39.9% |
| Attributable to shareholders of the company | 90.50 | 96.70 | −6.4% | 150.60 | −39.9% |
| EPS, basic (₹) | 5.42 | 11.60 | not comparable | 18.05 | not comparable |
| Net margin (%) | 13.9 | 16.4 | 20.8 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 632.10 | 528.10 | +19.7% | 699.60 | −9.6% |
| Other income | 26.60 | 29.50 | −9.8% | 22.80 | +16.7% |
| Total income | 658.70 | 557.60 | +18.1% | 722.40 | −8.8% |
| Profit before tax | 123.10 | 151.20 | −18.6% | 194.80 | −36.8% |
| Net profit for the period | 92.10 | 114.50 | −19.6% | 145.70 | −36.8% |
| EPS, basic (₹) | 5.52 | 13.74 | not comparable | 17.46 | not comparable |
| Net margin (%) | 14.6 | 21.7 | 20.8 |
Consolidated
- Filed with BSE
- 30 Jan 2026, 17:48 IST
- Board meeting
- 30 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jan 2026, 17:48 IST
- Board meeting
- 30 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE